Management of post-transplant lymphoproliferative disorders
Daan Dierickx, Vibeke Vergote
doaj +1 more source
A05 | TP53 in lymphoproliferative neoplastic disorders
TP53 disruption represents a central event driving clonal evolution, therapeutic resistance, and adverse outcome in several B-cell neoplasms, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma ...
Gian Matteo Rigolin
doaj
Molecular Insights and Novel Therapies for Lymphoproliferative Disorders. [PDF]
Wan S, Naik S.
europepmc +1 more source
Polyclonal evolution of lymphoproliferative disorders in XLP1. [PDF]
Tomomasa D +18 more
europepmc +1 more source
Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review. [PDF]
Mussi M +8 more
europepmc +1 more source
A Cautionary Tale: Urticaria and Angioedema As Presenting Signs of Lymphoproliferative Disorders. [PDF]
Kafashzadeh D, Kachru R.
europepmc +1 more source
HIV-associated lymphoproliferative disorders: Single-center experience. [PDF]
Demirtas D +13 more
europepmc +1 more source
Pediatric lymphoproliferative disorders - Emerging insights and management: A narrative review. [PDF]
Obeagu EI.
europepmc +1 more source
JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders. [PDF]
Geller S +8 more
europepmc +1 more source
Cell characterization of extranodal lymphoproliferative disorders. [PDF]
Muthumanickam P, Ramani P.
europepmc +1 more source

